Yubo International Biotech Ltd

Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing) Limited and related contractual arrangements. The business focuses on endometrial stem cell research and application, and markets a mix of healthcare products and stem cell-related services under the VIVCELL brand.

−8 258,0 %

66,1 %

−8 736,7 %

+256,0 %

0.24

0.23

— Yubo International Biotech Ltd
%
Stem cell research and services20% Research, testing, and consulting services centered on endometrial stem cells.
Respiratory healthcare products20% Consumer healthcare products positioned for respiratory wellness and related care.
Skincare and hair care products20% Beauty and personal care products sold under the VIVCELL brand.
Healthy beverages15% Functional beverage products marketed as part of the wellness portfolio.
Personal care products15% Male and female personal care products tied to the company’s consumer health offering.
Health management consulting10% Consulting services related to health management and cell-related wellness.

The company sells to a small number of customers, with historical revenue concentrated in a limited customer base in...

  • Consumer wellness customersprimary

    Buy branded healthcare, skincare, hair care, beverage, and personal care products for everyday use.

  • Stem cell service clientssecondary

    Use cell testing and health management consulting tied to the company’s stem cell platform.

  • Wholesale/distribution customersprimary

    Purchase product inventory or act as channel partners for the VIVCELL brand in China.

Yubo International Biotech is a U.S. holding company, but its operating activities are centered in Beijing, China...

  • U.S.-listed holding company with operating business in China
  • Principal executive offices are in Beijing, China
  • Day-to-day operations are conducted through Yubo Beijing
  • Chinese licenses and approvals are required to operate
  • Geographic exposure is concentrated in mainland China

The company’s strategy is centered on building its stem cell platform while commercializing a broader VIVCELL-branded...

01
Advance the stem cell platformmedium-term

The company’s differentiation depends on its endometrial stem cell research and related services.

02
Commercialize consumer wellness productsshort-term

Product sales provide a broader market beyond specialized stem cell services.

03
Preserve China operating accessshort-term

The business depends on PRC licenses, approvals, and contractual arrangements with the VIE.

The company faces concentration risk because historical revenue has come from a limited number of customers, and recent...

high

Customer concentration

Historical revenue has been generated from a limited number of customers, increasing dependence on a few buyers.

Scope
One customer accounted for 92% of sales in a prior quarter
Materiality
high
high

Operating and regulatory risk in China

The business requires PRC licenses and approvals to operate and is subject to local regulatory oversight.

Scope
Beijing operating entity and PRC permits
Materiality
high
high

VIE structure and contractual control risk

The listed parent does not directly own the PRC operating company, so control depends on contractual arrangements.

Scope
Yubo Beijing VIE structure
Materiality
high
medium

Product and compliance risk

Healthcare, personal care, and food-related products can face quality, labeling, and regulatory compliance issues.

Scope
Food Operation License Permit and medical distribution filing
Materiality
medium
Fair value measurements
Valuation assumptions can change earnings and balance sheet values
Earnings per share
Dilution and share structure may distort per-share comparability
Accrued expenses and contingencies
Expense recognition may shift between periods
VIE consolidation and related-party arrangements
Consolidation judgments affect what assets, liabilities, and revenue are reported

: 29/04/2026